- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06426836
Pediatrische antibioticadosering bij extracorporale membraanoxygenatie (PADECMO) (PADECMO)
Pediatrische antibioticadosering bij extracorporale membraanoxygenatie
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Pieter De Cock, PharmD
- Telefoonnummer: +32 9 332 29 69
- E-mail: pieter.decock@uzgent.be
Studie Locaties
-
-
-
Ghent, België, 9000
- Werving
- University Hospital
-
Contact:
- Pieter De Cock
- E-mail: pieter.decock@uzgent.be
-
Leuven, België, 3000
- Werving
- Universitair hospital
-
Contact:
- Debaveye Yves
- E-mail: yves.debaveye@uzleuven.be
-
-
Brussels Capital
-
Brussels, Brussels Capital, België, 1020
- Werving
- Queen Fabiola Children's University Hospital
-
Contact:
- Biarent Dominique
- E-mail: dominique.biarent@huderf.be
-
Contact:
- Vens Daphne
- E-mail: daphnevania.vens@huderf.be
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Exclusion Criteria:
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Amoxicillin-clavulanate
Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Andere namen:
|
|
Ander: Piperacillin-tazobactam
Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
Andere namen:
|
|
Ander: Meropenem
Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving meropenem as part of routine clinical care.
Andere namen:
|
|
Ander: Cefazolin
Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving cefazolin as part of routine clinical care.
Andere namen:
|
|
Ander: Vancomycin
Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving vancomycin as part of routine clinical care.
Andere namen:
|
|
Ander: Teicoplanin
Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving teicoplanin as part of routine clinical care.
Andere namen:
|
|
Ander: Ciprofloxacin
Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
Andere namen:
|
|
Ander: Amikacin
Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amikacin as part of routine clinical care.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Tijdsspanne: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Tijdsspanne: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Tijdsspanne: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Tijdsspanne: up to 1 month
|
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Tijdsspanne: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tijdsspanne: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tijdsspanne: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Tijdsspanne: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Tijdsspanne: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Tijdsspanne: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Tijdsspanne: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Tijdsspanne: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300 |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Tijdsspanne: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Tijdsspanne: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399 |
up to 1 month
|
|
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Tijdsspanne: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Tijdsspanne: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Tijdsspanne: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Tijdsspanne: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Tijdsspanne: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Tijdsspanne: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Annick de Jaeger, MD, University Hospital, Ghent
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Peptiden
- Aminozuren, peptiden en eiwitten
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Farmaceutische voorbereidingen
- Onderzoekstechnieken
- Exemplaarbehandeling
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Buren
- Chirurgische procedures, operatief
- Koolhydraten
- Glycosiden
- Amides
- Aminoglycosides
- Glycoconjugaten
- Drugscombinaties
- Penicilline g
- bèta-lactams
- Lactams
- Clavulaninezuur
- Clavulaninezuren
- Cephalosporins
- Thiazines
- Fluorochinolonen
- 4-quinolonen
- Chinolonen
- Chinolines
- Sulfonen
- Carbapenems
- Thienamycins
- Tazobactam
- Penicillaninezuur
- Piperacilline
- Glycopeptiden
- Ampicilline
- Penicillines
- Kanamycin
- Lipoglycopeptiden
- Amoxicilline
- Meropenem
- Piperacilline, Tazobactam Geneesmiddelencombinatie
- Vancomycine
- Amikacine
- Cefazoline
- Combinatie van amoxicilline en kaliumclavulanaat
- Teicoplanine
- Ciprofloxacine
- Bloedspecimenverzameling
Andere studie-ID-nummers
- BC-03512 (EC 2015/0529)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .